Stopped: Business decision
This is a first-in-human study evaluating the safety, tolerability, pharmacokinetics, immunogenicity and pharmacodynamics of single and multiple doses of HCR-188 administered as subcutaneous injection(s).
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Treatment-emergent adverse events
Timeframe: From the first dose and for up to 20 weeks
Treatment-emergent adverse events resulting in treatment discontinuation
Timeframe: From the first dose and for up to 20 weeks
Clinically significant laboratory values
Timeframe: From the first dose and for up to 20 weeks
Clinically significant vital signs
Timeframe: From the first dose and for up to 20 weeks
QT interval on ECG
Timeframe: From the first dose and for up to 20 weeks